Chaosi Electronics

Beijing Chaosi Electronic Technology Co., Ltd. (referred to as Chaosi) is a leading medical device manufacturer in China and one of the global innovators in pulse oximetry products. Since its establishment in 1993, Chaosi has been committed to the research, development, production, and sales of medical and health products, with product lines covering pulse oximetry series, home health series, and primary care medical series, dedicated to providing innovative medical and health products to medical institutions and families worldwide. With its headquarters in Beijing as the center, Chaosi's marketing network covers the globe, having established five subsidiaries in the United States, Canada, India, Germany, and Singapore. Its products meet the market access requirements of major economies such as China, the United States, the European Union, Canada, Japan, South Korea, and Brazil, and are sold in over 100 countries and regions. Chaosi products are available in globally renowned chain pharmacies, medical device stores, and large supermarkets, benefiting hundreds of millions of families and healthcare professionals worldwide. In 2016, Chaosi joined Tianjin Hongri Pharmaceutical Co., Ltd. (Stock Code: 300026), and within the group company's excellent big health industry cluster, it fully leverages its advantages in the intelligent, portable, and wearable medical device segment, combining with Internet, big data, artificial intelligence (AI) and other technologies for continuous innovation, achieving significant breakthroughs in the intelligent and wearable medical field! Tianjin Hongri Pharmaceutical Co., Ltd. was founded in 1996 and is one of the first enterprises listed on China's ChiNext board. After more than two decades of dedicated efforts, it has grown into a high-tech pharmaceutical and health industry cluster spanning finished drugs, traditional Chinese medicine granules, raw materials and excipients, medical devices, medical and health services, and intelligent supply chain for medical devices, integrating investment and financing, production, research and development, and sales. In recent years, the enterprise has continuously received honors such as National Key High-tech Enterprise, National Technological Innovation Demonstration Enterprise, National Advanced Collective in Poverty Alleviation, and First Prize of Tianjin Science and Technology Progress Award, and has consistently ranked among the top 100 pharmaceutical industries in China. In 2020, its main business revenue was 6.488 billion yuan, total assets were 10.18 billion yuan, and tax payment was 540 million yuan.